Literature DB >> 17983973

Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience.

Stephen Toovey1.   

Abstract

Purified rabies vaccine cultured on Vero cells (Verorab, sanofi pasteur) is WHO-approved for pre- and post-exposure prophylaxis by intradermal and intramuscular routes. During 20 years of use, over 40 million doses of Verorab have been administered in more than 100 countries. No serious adverse event due to Verorab has been reported in clinical trials involving 3937 persons, and Verorab is better tolerated than human diploid cell vaccine (HDCV). Pre-exposure prophylaxis is confirmed immunogenic in 1437 subjects by all routes, with prompt responses following boosting; Verorab boosts effectively subjects pre-immunized with HDCV. Unlike HDCV, Verorab is not associated with post-boosting serum sickness. In the absence of data in immunodeficient/HIV-positive individuals, pre-exposure immunization is urged as early as possible. Essen, Zagreb, Thai Red Cross Intradermal (TRC-ID) and other post-exposure intramuscular and intradermal regimens are documented. Two thousand one hundred and eighty-three subjects received post-exposure prophylaxis, including 874 high risk, severe or confirmed rabid attacks. Co-administration of rabies immune globulin (RIG) does not affect neutralizing antibody levels when Essen or TRC-ID regimens are employed; levels are lower with the Zagreb regimen. Verorab has been administered safely and effectively post-exposure to 251 pregnant women, without any increase in congenital malformations or spontaneous abortions. From a pediatric perspective, safety and efficacy have been demonstrated in 759 children (0-15 years). Intradermal post-exposure Verorab is an effective and inexpensive option for developing countries. Inadvertent subcutaneous administration does not reduce immunogenicity. WHO already strongly recommends the replacement of nerve tissue vaccines with modern vaccines. Extensive clinical experience supports the use of Verorab for intramuscular and intradermal pre- and post-exposure prophylaxis, including in special situations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17983973     DOI: 10.1016/j.tmaid.2007.07.004

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  10 in total

Review 1.  Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review.

Authors:  Marinos C Makris; Konstantinos A Polyzos; Michael N Mavros; Stavros Athanasiou; Petros I Rafailidis; Matthew E Falagas
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  Exposure to rabies during pregnancy.

Authors:  Catherine Windrim; Allison J McGeer; Kellie E Murphy
Journal:  CMAJ       Date:  2018-10-29       Impact factor: 8.262

Review 3.  Rhabdoviruses as vectors for vaccines and therapeutics.

Authors:  Gabrielle Scher; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2020-10-29       Impact factor: 7.090

Review 4.  Plant-based vaccines for animals and humans: recent advances in technology and clinical trials.

Authors:  Natsumi Takeyama; Hiroshi Kiyono; Yoshikazu Yuki
Journal:  Ther Adv Vaccines       Date:  2015-09

5.  Study of rabies virus by Differential Scanning Calorimetry.

Authors:  Audrey Toinon; Fréderic Greco; Nadège Moreno; Marie Claire Nicolai; Françoise Guinet-Morlot; Catherine Manin; Frédéric Ronzon
Journal:  Biochem Biophys Rep       Date:  2015-10-26

6.  Evervac: phase I/II study of immunogenicity and safety of a new adjuvant-free TBE vaccine cultivated in Vero cell culture.

Authors:  Mikhail F Vorovitch; Karina G Grishina; Viktor P Volok; Liubov L Chernokhaeva; Konstantin V Grishin; Galina G Karganova; Aidar A Ishmukhametov
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

7.  Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis.

Authors:  Shi-Yuan Wang; Jin-Fang Sun; Pei Liu; Li Luo; Jing-Xin Li; Feng-Cai Zhu; Xu-Xiang Shen; Fan-Yue Meng
Journal:  Hum Vaccin Immunother       Date:  2022-02-22       Impact factor: 3.452

8.  Travelers' vaccines and their adverse events in Nara, Japan.

Authors:  Taku Ogawa; Nobuyasu Hirai; Natsuko Imakita; Hiroyuki Fujikura; Akihiro Kajita; Yuichiro Imai; Tomoko Onishi; Masahiro Takeyama; Kei Kasahara
Journal:  Open Med (Wars)       Date:  2021-06-30

9.  Human rabies in Côte d'Ivoire 2014-2016: Results following reinforcements to rabies surveillance.

Authors:  Issaka Tiembré; Anaïs Broban; Joseph Bénié; Mathilde Tetchi; Sophie Druelles; Maïna L'Azou
Journal:  PLoS Negl Trop Dis       Date:  2018-09-06

10.  Improving systematic rabies surveillance in Cameroon: A pilot initiative and results for 2014-2016.

Authors:  Casimir Ledoux Sofeu; Anaïs Broban; Amadou Njifou Njimah; Jean Blaise Momo; Serge Alain Sadeuh-Mba; Sophie Druelles; Maïna L'Azou; Mathurin Cyrille Tejiokem
Journal:  PLoS Negl Trop Dis       Date:  2018-09-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.